Background-Microbubble safety concerns led to changes in product recommendations for patients with pulmonary hypertension. Noninvasive estimation of right ventricular systolic pressure (RVSP) is equivalent to pulmonary artery systolic pressure in the absence of pulmonary outflow obstruction. We analyzed the short-and long-term outcomes of patients who received microbubble contrast and those who did not during stress echocardiography (SE) according to resting RVSP.
C oncerns regarding a "safety signal" for perflutrencontaining contrast agents followed postmarketing surveillance reports of adverse events and led to subsequent changes in the recommendations for product use in the United States. On October 12, 2007 , the Food and Drug Administration (FDA) issued a "black box" warning for both perflutren-containing agents (Definity, Lantheus Medical Imaging, North Billerica, Mass; and Optison, GE Healthcare Inc, Princeton, NJ). This warning emphasized the risks of serious cardiopulmonary reactions of ultrasound contrast agents and included additional contraindications to the use of these agents in patients with acute myocardial infarction, worsening or clinically unstable heart failure, serious ventricular arrhythmias, respiratory failure, severe emphysema, pulmonary emboli, or other conditions that cause pulmonary hypertension due to compromised pulmonary arterial vasculature. 1
Clinical Perspective on p 248
Following these warnings, the echocardiographic practice pattern was altered amid a disparity of opinion and ongoing discussion regarding their implications. 2 Subsequently, on May 12, 2008, revised labeling changes, including a relaxation of previous warnings, were implemented by the FDA and were simplified to include only the following contraindications to the administration of contrast agents: patients with known or suspected right-to-left, bidirectional or transient right-to-left cardiac shunts, and hypersensitivity to fluorocarbon. However, in patients with pulmonary hypertension (degree not specified) or unstable cardiopulmonary conditions, the FDA continued to recommend the close monitoring of vital signs, ECG, and cutaneous oxygen saturation during and for 30 minutes after administration of contrast agents. 1 The right ventricular systolic pressure (RVSP) is equivalent to pulmonary artery systolic pressure in the absence of distal obstruction including right ventricular outflow tract obstruction, pulmonary valve stenosis, or supravalvular stenosis. RVSP measurements obtained by Doppler echocardiography correlate well with those obtained from simultaneous invasive cardiac catheterization studies. 3, 4 In the present study, we evaluated the safety of contrast agents used during stress echocardiography (SE) in patients with elevated RVSP as determined by the peak tricuspid regurgitant velocity. The short-and long-term end points considered were death and myocardial infarction (MI). We hypothesized that the use of contrast agents would not result in harm to patients with elevated resting RVSP who are undergoing SE.
Methods
This retrospective cohort study was approved by the Mayo Clinic Institutional Review Board. Only patients who approved the use of their medical records for research were included in the study. This manuscript was written in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. 5
Identification of Study Cohorts
We used the Mayo Clinic Stress Echocardiography Database to identify the study population. We identified 26 774 patients who underwent their first SE between November 1, 2003, and December 31, 2007, at Mayo Clinic, Rochester, Minnesota. We initially evaluated the entire group of patients and found no increase in the short-or long-term rates of death or MI in those receiving contrast compared with those who did not. 6 In this report, we studied the subgroup of 16 434 patients who had RVSP measured at rest to evaluate the safety of contrast in patients with pulmonary hypertension. The contrast cohort comprised patients who received contrast agents during SE; the noncontrast cohort comprised the remaining patients who had SE during the same period but who did not receive contrast agents.
Contrast Agents
The contrast agents used during the study were the commercially available FDA-approved fluorocarbon-based agents: Optison and Definity. Contrast agents were administered for left ventricular opacification according to the American Society of Echocardiography Task Force on Standards and Guidelines for the Use of Ultrasonic Contrast in Echocardiography. 7 The contrast agents were administered as an intravenous bolus, in accordance with the package inserts.
Stress Echocardiography Protocol
Patients in both cohorts had SE with dobutamine or exercise, according to the American Society of Echocardiography standards. 8 Dobutamine SE was performed according to a standard protocol and standard end points as previously described 9 ; for exercise SE, the symptom-limited Bruce protocol was performed according to a standard protocol and end points. 10 Commercially available ultrasound systems were used: SONOS 7500 or iE33 (Philips Medical Systems, Andover, Mass), ACUSON Sequoia 512 (Siemens Medical Solutions, Mountain View, Calif), and Vivid 7 (GE Healthcare, Princeton, NJ). Twelve-lead ECG, heart rate, and blood pressure were monitored continuously at each stage of SE and continued until the recovery heart rate was within 20 beats of the baseline heart rate. In the contrast cohort, any symptoms potentially attributable to contrast agent infusion were recorded. For purposes of analysis, a 16-segment left ventricle model was used, and all segments were graded using the wall motion score index. The rest and stress ejection fraction were determined.
RVSP Measurements
During the same SE study, RVSP evaluation was obtained from standard 2D views to image the tricuspid valve; Color Doppler was then used to detect the presence of tricuspid regurgitation (TR). If TR was present, continuous wave Doppler was used to measure the maximal velocity of the regurgitant jet, taking care to optimize the transducer position in an attempt to record the highest maximal velocity on the spectral display. Using the simplified Bernoulli equation, the systolic transtricuspid gradient was calculated as 4 V 2 (Vϭthe maximal TR velocity in ms Ϫ1 ). 11 RVSP was estimated by the formula 4 V 2 ϩRAP, where RAP is right atrial pressure. Echocardiographic determination of the RAP was made according to the size of the inferior vena cava diameter, and the relative change in dimension during inspiration [5 mm Hg was assigned to a small (Ͻ1.0 to 1.5 cm) vena cava collapsing Ͼ50% in diameter; 20 to 25 mm Hg to a dilated vena cava (Ͼ2.0 cm) without respiratory variation in size, and values of 10 to 15 mm Hg to intermediate findings]. 12
Data Collection and Outcome Measurements
Patient characteristics and echocardiographic parameters including RVSP and peak TR velocity were prospectively recorded in the SE database. The primary outcome of this study was the short-term safety (Յ72 hours and Յ30 days) of contrast agents administered to patients with elevated RVSP. End points analyzed were death (all-cause mortality) and MI after SE. The secondary outcome was the long-term safety of contrast agent use and the time to event (death or MI). Deaths were identified by first searching the SE Database and the Mayo Clinic Death Database. A thorough chart review was then conducted to confirm the death and the date of occurrence in relation to contrast agent administration. For identification of MI, we used the International Classification of Diseases, Ninth Revision (ICD-9) code 410. 13 Chart reviews were conducted to verify patients reported to have MI after SE. Arrhythmias, including ventricular tachycardia (VT), were also reported. Sustained VT was defined as a regular wide QRS complex tachycardia of more than 100 beats per minute lasting for 30 seconds or more or resulting in hemodynamic collapse requiring medical or electric therapy. Nonsustained VT was defined as VT for Ն3 beats but with duration of Ͻ30 seconds. Finally, we reported on the electronically documented adverse effects related to contrast agents for the year 2007.
Statistical Analysis
Patient characteristics and SE data were summarized with count and percentage data for categorical variables and meanϮSD for continuous variables. For categorical variables, differences between cohorts were tested by using the Pearson 2 test or Fisher exact test, as appropriate. For continuous variables, differences between groups were tested by using the 2-sample t test. Patients were categorized into RVSP groups. Pulmonary hypertension was defined by RVSP values of Ն35, Ն50, and Ն60 mm Hg. 14 TR velocities Ն2.7 ms Ϫ1 and Ն3.5 ms Ϫ1 were also used. The optimal data cut-point of 35 mm Hg was derived by the method of Contal and O'Quigley. 15 Similar categorization was performed for TR velocity where the optimal data cut-point of 2.7 ms Ϫ1 was derived by the same statistical method. Survival curves for long-term events during follow-up were estimated by the Kaplan-Meier method and compared between groups using the log-rank test. Cox proportional hazards modeling was used to examine the association between contrast use and the end points (death or MI) and to adjust for known or suspected confounders. To check for violations of the proportional hazards assumption for each variable, Schoenfeld residuals were visually inspected and a formal correlation test was performed to examine the association between the residual for each variable and the rank transformed follow-up time. We found no violations of the proportional hazards assumptions. As a supplemental analysis within each RVSP and TR group, comparison of long-term outcomes between patients receiving contrast and those not receiving contrast was performed by propensity matching analysis. To calculate propensity scores, a logistic regression model was fit including all relevant variables and the propensity for receiving contrast was taken as the predicted value from this model. Each patient receiving contrast was then matched on propensity score to a patient not receiving contrast. To ensure that a good match was made, the maximum allowable difference in propensity score was 0.25 SD. Because of this constraint, a match was not available for some contrast patients. Additionally, interpretations were based on the upper 95% confidence limits for adjusted hazard ratios to give an indication as to what level of harm we can exclude for contrast agents, as in a noninferiority analysis. In all analyses, significance was set at a 2-sided probability value of 0.05. All analyses were performed with SAS, version 9.1 software (SAS Institute Inc, Cary, NC).
Results
Of 26 774 patients who underwent SE between November 1, 2003, and December 31, 2007, at Mayo Clinic, Rochester, Minnesota, resting RVSP determination was feasible in 16 434 patients ( Figure 1 ). The mean age was 65.4Ϯ13.3 years; 8355 (51%) were male; and body mass index was 28.3Ϯ5.6 kg/m 2 . Mean resting RVSP was 32.6Ϯ9.6 mm Hg, and the TR averaged 2.56Ϯ0.37 ms Ϫ1 . The contrast cohort included 6164 patients (39% had exercise SE and 61% had dobutamine SE). The noncontrast cohort included 10 270 patients (60% had exercise SE and 40% had dobutamine SE). Patients in the contrast cohort were more likely to have coronary artery disease. In addition, they had a higher percentage of positive SE (35%) compared with those in the reference cohort (30%, PϽ0.001) ( Table 1 ).
In the contrast cohort 1900 (31%) patients had RVSP Ն35 mm Hg, 414 (7%) patients had RVSP Ն50 mm Hg, and 118 (2%) patients had RVSP Ն60 mm Hg. In the noncontrast cohort, 2655 (26%) patients had RVSP Ն35 mm Hg, 611(6%) patients had RVSP Ն50 mm Hg, and 186 patients (2%) had RVSP Ն60 mm Hg. With regard to TR velocity in the contrast cohort, 2367 (38%) patients had TR peak velocity Ն2.7 ms Ϫ1 and 157 (3%) patients had TR peak velocity Ն3.5 ms Ϫ1 . Clinically important pulmonary hypertension (RVSP Ն50 mm Hg) was present in more patients in the contrast cohort and was associated with more cardiac risk factors compared with patients who did not receive contrast ( Table 2 ).
Short-Term Safety of Contrast SE
Even though it included higher-risk patients, the contrast cohort categorized by RVSP of Ն35, Ն50, or Ն60 mm Hg or by TR velocity values Ն2.7 ms Ϫ1 or Ն3.5 ms Ϫ1 had similar short-term event rates (Յ72 hours and Յ30 days) for deaths and MI compared with those of the noncontrast cohort ( Table  3 and Table 4 ).
Mortality at <72 Hours
Within 72 hours after SE, 1 patient in the contrast cohort and 2 patients in the noncontrast cohort died. The patient in the contrast cohort who died was a 76-year-old woman with diabetes mellitus who underwent dobutamine SE as part of a preoperative evaluation for repair of a mycotic aortic aneurysm. Baseline transthoracic echocardiography (TTE) showed a peak TR velocity of 3.20 ms Ϫ1 and RVSP pressure of 46 mm Hg. SE results were normal with no reported side effects from contrast agents. The patient died of cardiac and multiorgan failure on the second postoperative day.
MI at <72 Hours
Three patients in the contrast cohort and 5 in the noncontrast cohort had MI within 72 hours after SE. All 3 in the contrast cohort had dobutamine SE (1 received Definity; 2 received Optison). One patient in the contrast cohort who had MI was a 65-year-old man with diabetes mellitus, hypertension, and hyperlipidemia; he underwent dobutamine SE before orthopedic surgery. Baseline TTE showed a peak TR velocity of 2.4 ms Ϫ1 and RVSP pressure of 28 mm Hg. SE results were markedly positive for ischemia in the left anterior descending coronary artery distribution. Ventricular fibrillation developed during the SE recovery period and required emergent defibrillation. Three hours after the SE, the cardiac troponin T level was elevated (0.05 ng/mL, reference range Յ0.03 ng/mL). The patient underwent urgent coronary angiography and stenting of the left anterior descending coronary artery, which was totally occluded. Another patient in the contrast 
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cohort who had MI after SE was a 73-year-old woman who smoked and had diabetes mellitus, hypertension, and hyperlipidemia; she underwent dobutamine SE before orthopedic surgery. Baseline TTE showed a peak TR velocity of 2.9 ms Ϫ1 and RVSP pressure of 44 mm Hg. SE was negative for myocardial ischemia. Four hours after SE, the patient underwent hip replacement. On the second postoperative day, she had chest pain and an elevated cardiac troponin T level (0.23 ng/mL). Non-ST-segment elevation MI was diagnosed; she underwent coronary angiography, and a high-grade stenosis of the obtuse marginal branch of the left circumflex artery was stented. The third patient in the contrast cohort who had MI was a 68-year-old man with renal cell carcinoma. He underwent dobutamine SE for assessment of possible coronary artery disease. Baseline TTE showed a peak TR velocity of 2.5 ms Ϫ1 and RVSP pressure of 30 mm Hg. He had severe chest pain during the SE. The stress ECG was normal, and no stress-induced regional wall motion abnormalities were seen. The patient was transferred to the emergency department for observation, and 3 hours later, the cardiac troponin T was elevated (0.08 ng/mL). Non-ST-segment elevation MI was diagnosed, and coronary angiography showed moderate stenosis (60%) of the left circumflex coronary artery and 50% stenosis of the right coronary artery.
Mortality and MI at <30 Days
Within 30 days after SE, a total of 26 patients (0.42%) in the contrast cohort died and 38 patients (0.37%) in the reference cohort died. Ten patients (0.16%) in the contrast cohort had MI, similar to the noncontrast cohort [14 patients (0.14%).
Ventricular Arrhythmias
There was no significant difference between the proportion of patients in each cohort who had VT. For RVSP Ն50 mm Hg, no VT was reported in the contrast cohort, and 1 (0.2%) patient in the noncontrast cohort had VT. Figure 2 and Figure 3 . Because the patient population was studied as a whole and the thresholds for RVSP were then applied, it is important to note that the curves in the figures are not independent; patients in the subgroup with the highest RVSP appear in all 3 graphs shown for each figure. Also important to note is that we tested the statistical interaction between RVSP, as determined by TR velocity, and contrast on the entire population and found no strong evidence of any interaction, suggesting that the risk of events between those with and without contrast are similar regardless of RVSP or TR velocity. Univariate analysis using Cox proportional hazard ratios showed several baseline characteristics that were significantly associated with long-term outcome (death or MI). Older age, male sex, body mass index, diabetes, previous coronary artery disease, resting ejection fraction, and result of SE were associated with worse outcomes (death, or MI). After adjustment for these variables, there was no evidence that the contrast and noncontrast groups were different in terms of either death or MI. However, with these data it is not possible to exclude up to a 1.5-fold relative increase in mortality or up to a 1.2-fold relative increase in MI for the increased (Ն35 mm Hg) RVSP group (Table 5 ). Additionally, we performed a separate analysis to compare outcomes of all patients with increased RVSP (Ն35 mm Hg) compared with all patients with normal (Ͻ35 mm Hg) RVSP, and such analysis revealed a significant increase in the mortality rates, and/or MI in the group of increased (Ն35 mm Hg) RVSP with HR for death (2.8 [95% confidence interval (CI)], 2.4, 3.1), PϽ0.001) and HR for MI (1.9 [95% CI, 1.5, 2.4]), PϽ0.001.
Adverse Effects Related to Contrast Agents
Adverse effects of contrast agents during SE testing were documented in the electronic database starting in January 2007. Among the 3071 patients who underwent contrast SE in 2007, 1838 had baseline RVSP measurements, and in these patients, contrast agents were suspected to be the cause of adverse reactions in 28 (1.5%), and a definite relation with contrast agent infusion was established in 18 of the 1838 patients (0.98%). Backache alone was reported in 12 of 1838 patients (0.65%), headache alone in 3 (0.16%), and both in 3 patients (0.16%). Transient wheez-ing without urticaria was reported in 1 patient (0.05%) undergoing dobutamine SE, and baseline RVSP was 32 mm Hg. Other side effects included abdominal pain in 1 patient (0.05%) and throat tingling in 1 patient (0.05%). The adverse reactions thought to be caused by concomitant infusion of contrast agent and dobutamine were chest pain in 10 patients (0.54%), nausea and vomiting in 1 patient (0.05%), and shivering and tremors in 3 patients (0. 16%).
Discussion
This retrospective cohort study addressed the safety of ultrasound contrast agent use during SE in patients with increased RVSP as determined by resting TR peak velocity. During short-term and long-term follow-up, patients who had SE with contrast agents and who were categorized by RVSP Ն35 mm Hg, Ն50 mm Hg, and Ն60 mm Hg or TR peak velocity Ն2.7 ms Ϫ1 or Ն3.5 ms Ϫ1 showed no association between rates of death or MI and contrast agent use. There was no difference in rates for death or MI compared with those who had not received contrast agent, despite a higher incidence of clinical comorbidities in the contrast cohort. Based on the upper limit of the confidence interval for patients with RVSP Ն50, the data exclude a HR for a relative increase in mortality of Ͼ1.5. Additionally, the large number of patients included in the present study allowed for adjustment of factors that might confound a potential association 
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between the use of a contrast agent and incremental risk for a cardiovascular event. Finally, contrast agent-related side effects were minor and infrequent (reported for Ͻ1% of patients) and had no relationship to RVSP. Although the FDA relaxed its warnings on May 12, 2008, additional monitoring is still recommended in patients with pulmonary hypertension (degree unspecified) and those with unstable cardiopulmonary conditions. Although patients with unstable cardiopulmonary conditions are most often in an ICU setting where they are being monitored, confusion remains regarding the need for monitoring patients who have pulmonary hypertension. RVSP can be reliably estimated noninvasively, using echocardiographic techniques. We used RVSP as a surrogate measurement of pulmonary artery systolic pressure and classified the study population by RVSP. We have shown comparable event rates in patient groups regardless of contrast administration or degree of RVSP elevation.
In 2008, there was considerable debate about the safety of contrast agents in response to the FDA black box warnings. Both single-center and large multicenter retrospective analyses have subsequently demonstrated a good safety profile with a favorable balance of risks and benefits in the use of ultrasound contrast agents. 16 -25 Contrast agent-related adverse effects in the present study were generally minor and occurred in Ͻ1% of patients. Some of these adverse effects were attributed to contrast agent administration, as evidenced by their reversal after decreasing the dose or discontinuing the administration of the contrast agent. Other adverse effects, including chest pain, arrhythmias, and shortness of breath, were thought related to the sympathomimetic effects of the pharmacological stress agent dobutamine. These adverse effects were subjectively assessed and carefully reported by the responsible echocardiography laboratory personnel, including nurses, sonographers, and physicians, in part using an electronic information management system; however, it is still possible that misrepresentation and/or underreporting may have existed. In general, the safety of echocardiographic stress testing is recognized and has been demonstrated previously in our SE laboratory. 26 These data represent the results of a single-center retrospective experience and should be interpreted in that context. There are limitations inherent to the retrospective nature of this study. Only 16 434 of the 26 774 patients undergoing SE in the period of interest had resting RSVP measured. We acknowledged the potential existence of selection bias. To evaluate this possibility, a post hoc comparison of patient characteristics and event rates was performed between patients who had RVSP reported and those who did not. This comparison did not show any significant variation between the 2 cohorts either by univariate or multivariate analysis.
Death and MI were selected as the main end points of the study because they can be identified objectively and are easily retrievable from the medical record with high accuracy and precision. Although hospital records were thoroughly reviewed for end point events, some patients may not have sought medical care for complications arising after hospital discharge or may have sought medical care at a different institution. Thus, the end point events may be underreported. Echocardiographic assessment of TR is considered to be an accurate technique. Underestimation and overestimation of TR can occur, and this may influence the calculation of RVSP. However, the reported sensitivity of TR velocity method for detecting pulmonary hypertension ranges from 79% to 100% and specificity from 60% to 98%. 14 Indeed, the noninvasive hemodynamic assessment of intracardiac pressures is a well-established cornerstone in the practice in 2D/Doppler echocardiography, with a well-documented literature of comparative catheterization studies. 3, 4 The strengths of this current study are the large, well-characterized population, the cohort design, and the accessibility of detailed clinical information included in the electronic record, allowing thorough evaluation of potential associations between contrast agent use and the events of interest through multivariate analysis. The data are from a high-volume echocardiography laboratory for primary care and referral practices. However, the results may not be valid for other populations because of variations in clinical practice, clinical settings, or patient characteristics. Further validation studies may be necessary for unique patient populations.
In summary, in this study population, the use of contrast agents during SE in patients with elevated RVSP determined from TR velocity measurements as a measure of pulmonary hypertension was not associated with increased short-term or long-term rates of death or MI. The study also provided further evidence for the safety of contrast agent use during SE in particular.
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